Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.